Challenges and lessons learned from a long-term postauthorisation safety study programme of rivaroxaban in Europe

Autor: Luis Alberto García Rodríguez, Montse Soriano-Gabarró, Pareen Vora, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Ana Ruigomez, Leif Friberg, Ron Herings, Karin M A Swart, Tania Schink, Elisabeth Smits, Annemarie Voss, Christine Tarenz, Martin Homering, Tomasz Dyszynski, Gerd Nagel, Pablo Amaya

Publikováno v: BMJ Open, Vol 14, Iss 3 (2024)

Objectives To describe opportunities and challenges experienced from the four pharmacoepidemiological database studies included in the rivaroxaban post authorisation safety study (PASS) programme and propose ways to maximise the value of population-b

Externí odkaz: https://doaj.org/article/71cd625a0f2244c3a4bb82474e3418be

Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care

Autor: Luis Alberto García Rodríguez, Pareen Vora, Luke Roberts, Gunnar Brobert, Samuel Fatoba, María Eugenia Sáez, Antonio González-Pérez

Publikováno v: BMJ Open, Vol 12, Iss 6 (2022)

Externí odkaz: https://doaj.org/article/32d4d86ecd8e4df7aa2725edd2fc8029

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism (deep vein thrombosis and pulmonary embolism) in four European countries

Autor: Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M. C. Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez

Background The European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical prac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dc0803de5229a790f8e984c72eae187e
https://doi.org/10.21203/rs.3.rs-2664836/v1

Association of Long-term Statin Use With the Risk of Intracerebral Hemorrhage

Autor: Daniel Albjerg Rudolph, Stine Munk Hald, Luis Alberto García Rodríguez, Sören Möller, Jesper Hallas, Larry B. Goldstein, David Gaist

Publikováno v: Neurology. 99:e711-e719

Background and ObjectivesA causal relationship between long-term statin use and the risk of intracerebral hemorrhage (ICH) remains uncertain. We investigated the association with statin use before hospital admission for ICH in a Danish population–b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29ab4537f9fe301a9ccaf200bf451f25
https://doi.org/10.1212/wnl.0000000000200713

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

Autor: Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, Matthew A Cavender, Anna Norhammar, Marit E Jørgensen, Kåre I Birkeland, Reinhard W Holl, Josep Franch-Nadal, Navdeep Tangri, Jonathan E Shaw, Jenni Ilomäki, Avraham Karasik, Su-Yen Goh, Chern-En Chiang, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Johan Bodegård, Filip Surmont, Peter Fenici, Mikhail Kosiborod, John P Wilding, Kamlesh Khunti, Kåre Birkeland, Marit Eika Jørgensen, Reinhard W. Holl, Carolyn SP Lam, Hanne Løvdal Gulseth, Bendix Carstensen, Esther Bollow, Luis Alberto García Rodríguez, Jonathan Shaw, Suzanne Arnold, Betina T. Blak, Eric T. Wittbrodt, Matthias Saathoff, Yusuke Noguchi, Donna Tan, Maro Williams, Hye Won Lee, Maya Greenbloom, Oksana Kaidanovich-Beilin, Khung Keong Yeo, Yong Mong Bee, Joan Khoo, Agnes Koong, Yee How Lau, Fei Gao, Wee Boon Tan, Hanis Abdul Kadir, Kyoung Hwa Ha, Jinhee Lee, Gabriel Chodick, Cheli Melzer-Cohen, Reid Whitlock, Lucia Cea-Soriano, Oscar Fernándex Cantero, Jordan A. Menzin, Matthew Guthrie, Jennie Ilomaki, Dianna Magliano

Publikováno v: Kohsaka, S, Lam, C S P, Kim, D J, Cavender, M A, Norhammar, A, Jørgensen, M E, Birkeland, K, Holl, R W, Franch-Nadal, J, Tangri, N, Shaw, J, Ilomäki, J, Karasik, A, Goh, S Y, Chiang, C E, Thuresson, M, Chen, H, Wittbrodt, E, Bodegård, J, Surmont, F, Fenici, P & Kosiborod, M 2020, ' Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors : an analysis from the CVD-REAL 2 multinational cohort study ', The Lancet Diabetes and Endocrinology, vol. 8, no. 7, pp. 606-615 . https://doi.org/10.1016/S2213-8587(20)30130-3
Lancet Diabetes & Endocrinology, 8(7), 606-615. ELSEVIER SCIENCE INC

Background: Cardiovascular outcome trials have shown cardiovascular benefit with sodium-glucose co-transporter-2 (SGLT2) inhibitors in patients with type 2 diabetes, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors have not shown an effect. We aimed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68860c6556bbf38e0e25d66268d78e6f
https://doi.org/10.1016/s2213-8587(20)30130-3